Sunday, February 23rd, 2025

CSE Global: Strengthening Market Position with Robust Order Pipeline and Strategic Growth Initiatives

Date of Report: 3 October 2024
Broker: UOB Kay Hian


Robust Order Pipeline

CSE Global continues to enjoy strong order wins, reporting an order intake of S$391 million in the first half of 2024. While this figure remains flat year-on-year, it signals a healthy order pipeline for the coming quarters.


Growing Orderbook

The company’s orderbook has reached S$692 million, representing a 33% year-on-year increase. The infrastructure segment constitutes the majority of the orderbook, accounting for 72%. This growth reflects CSE Global’s strategic focus on emerging trends in electrification and decarbonization.


Business Development Strategy

CSE Global is actively pursuing acquisitions in the critical communications space in the Americas region to enhance its growth strategy. The company is also focusing on data center and automation projects to seize emerging market opportunities.


Positive Financial Performance

CSE Global has reported stable financial performances in both the infrastructure and mining & minerals sectors. This stability is bolstered by a consistent stream of projects arising from global requirements in digitalization, physical and cyber security enhancements, and demands from data centers and water utilities in both the Americas and Asia-Pacific regions.


Investment Recommendation and Target Price

UOB Kay Hian maintains a “BUY” recommendation for CSE Global, with a target price of S$0.60. This target is based on a price-to-earnings (PE) ratio of 13x for 2024, which reflects a valuation of 1 standard deviation above the mean.


Key Catalysts for Growth

Key events that could drive CSE Global’s share price higher include:

  • Winning large infrastructure projects.
  • Successful acquisitions that enhance service capabilities.
  • Increased demand for automation solutions in response to global market trends.

Malaysia Stock Market: Top Picks and Technical Analysis for November 2024

Comprehensive Analysis of Key Malaysian Companies Comprehensive Analysis of Key Malaysian Companies Broker: CGS International Date of Report: November 21, 2024 Gamuda Berhad: Aiming for a New High Gamuda Berhad, an investment holding and...

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals 🏢 Sino Biopharmaceutical (1177 HK) – Leading the Charge with Innovative Drug Development Recommendation: BUY Target Price: Not specified Stop Loss: Not...

SATS and SGX

SATS (SGX: S58): Price Correction Ahead, Trading Sell Recommendation: Trading Sell Target Price: S$3.35 Protective Stop: S$3.76 Date of Recommendation: September 9, 2024 Broker Company: UOB Kay Hian Investment Thesis: SATS, a major player...